Skip to main content
GRFSGrifols, S.A.Sell6.0·$8.63
SellModerate Confidence
Investment thesis

Grifols is cheap (forward P/E 7.0x, 57% margin of safety) with strong earnings growth and volume accumulation, but it has missed EPS 4 times running, has weak cash conversion and trades within 1.4% of its analyst target.

Thesis pillars

  • Deep Value Margin Of Safety→Stable
  • Strong Growth Profile→Stable
  • Repeated Earnings Misses↑Improving
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026

Full reasoning →

Open full analysis

Grifols, S.A. (GRFS) Stock Analysis

Momentum Cont setup

SellGrowthModerate Confidence

Healthcare · Drug Manufacturers - General

Sell if holding. Analyst target reached at $8.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies,... Read more

$8.63+2.1% A.UpsideScore 6.0/10#2 of 16 Drug Manufacturers - General
QualityF-score8 / 9FCF yield3.31%
IncomeYield1.21%(5y avg 2.14%)Payout12.74%sustainable
Stop $8.13Analyst target $8.81(−15% haircut)A.R:R 0.1:1
Analyst consensus$10.37+20.1%2 analysts with price targets
$8.81Analyst target
$8.63price
$10.37mean
$12

Sell if holding. Analyst target reached at $8.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5. Chart setup: Trend continuation, RSI 67, MACD bullish. Score 6.0/10, moderate confidence.

Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 99d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 4, 2026

Recent Developments — Grifols, S.A.

Latest item Nov 4, 2026 · Generated 2026-11-18T11:37:42Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Feb 25, 202799d to earnings· next earnings call

Thesis

Rewards
Attractive valuation
Strong growth profile
Margin of safety: 58%
Risks
Analyst target reached - limited upside remaining
Leverage penalty (D/E 1.1): -0.5
Consecutive earnings misses (4)

Key Metrics

P/E (TTM)10.4
P/E (Fwd)6.9
Mkt Cap$5.9B
EV/EBITDA13.2
Profit Mgn6.4%
ROE7.3%
Rev Growth9.4%
Beta1.13
Dividend1.21%
Analysts with ratings21

Quality Signals

Piotroski F8/9

Options Flow

P/C0.04bullish
IV162%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
Dividend Safety
6.8
Earnings concerns: 0B/4M
GatesA.R:R 0.1 < 1.5@spotDeath cross (50MA < 200MA)Momentum 4.6<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.6>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 99d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARMomentum ContSuitability: Moderate
RSI
67 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $7.37Resistance $8.89

Price Targets

$8
$9
A.Upside+2.1%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (2.1% upside)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot
! Death cross — 50-day MA below 200-day MA

Earnings

M
M
M
M
0/4 beats
Next Earnings2027-02-25 (99d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is GRFS stock a buy right now?

Sell if holding. Analyst target reached at $8.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5. Chart setup: Trend continuation, RSI 67, MACD bullish. Prior stop was $8.13. Score 6.0/10, moderate confidence.

What is the GRFS stock price target?

Analyst target: $8.81 (+2.1% upside). Prior stop was $8.13. Stop-loss: $8.13.

What are the risks of investing in GRFS?

Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5; Consecutive earnings misses (4).

Is GRFS overvalued or undervalued?

Grifols, S.A. trades at a P/E of 10.4 (forward 6.9). TrendMatrix value score: 8.9/10. Verdict: Sell.

What do analysts say about GRFS?

21 analysts rate GRFS, with a consensus score of 3.8/5. 2 analysts publish price targets averaging $10.

What does Grifols, S.A. do?Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of...

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Related stocks: BIIB (Biogen Inc.) · OGN (Organon & Co.) · ANIP (ANI Pharmaceuticals, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ASND (Ascendis Pharma A/S)
Home › Stocks › GRFS

Latest news

Latest News

TipRanks112d agoEarnings
The Motley Fool112d agoEarnings
The Globe and Mail112d agoEarnings
Yahoo Finance112d agoEarnings
Investing.com112d ago
Seeking Alpha113d agoEarnings
TradingView113d agoEarnings
Yahoo Finance113d agoEarnings
Investing.com113d agoEarnings
Yahoo Finance113d ago
Quiver Quantitative113d ago
Marketscreener.com113d agoEarnings
Simplywall.st120d ago
Moomoo118d agoEarnings
TradingKey116d ago
DirectorsTalk Interviews114d ago
TradingKey114d ago
TradingKey114d ago
Dars.gov.et121d ago
TipRanks121d agoProduct
Loading more...